COMMUNIQUÉS West-GlobeNewswire

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
30/10/2025
HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the [...]
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
30/10/2025
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
30/10/2025
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics MALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- [...]
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
30/10/2025
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- [...]
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
30/10/2025
HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat [...]
Flare Therapeutics to Present Correlative Biomarker Analysis from the FX-909 Phase 1A Clinical Study at Upcoming SITC 2025 40th Anniversary Annual Meeting
30/10/2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
Avance Clinical Launches Renal and Cardiometabolic Center of Excellence to Optimize Patient Recruitment to Elevate Study Success
30/10/2025
ADELAIDE, Australia, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Avance Clinical , a partner for biotechs providing global contract research organization services, has announced the launch of the Renal & Cardiometabolic [...]
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and [...]
WeightWatchers Schedules Third Quarter 2025 Earnings Conference Call
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) will release its results for the third quarter 2025 ended September 30, 2025, before market open [...]
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
30/10/2025
BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients [...]
Nouscom to Present New Positive Phase 1b/2 Clinical and Translational Data on NOUS-209 Immunogenicity and Cancer Interception Potential in Lynch Syndrome Carriers at SITC 2025
30/10/2025
Lynch Syndrome (LS) is a common hereditary condition that greatly increases lifetime risk of colorectal, endometrial, urothelial and other cancers NOUS-209 is an off-the-shelf immunotherapy designed to harness the power [...]
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
30/10/2025
WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
30/10/2025
Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for [...]
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
30/10/2025
Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform PHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “ [...]
Kaida BioPharma Selected to Present at Two Upcoming Conferences
30/10/2025
Premier presenter semi-finalist for BIOPITCH at the Florida Innovation Conference Startup finalist for Tampa Tank Pitch Competition at the Disrupt the Bay Conference featuring Keynote Speaker, Cathie Wood from Ark [...]
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
30/10/2025
ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant [...]
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
30/10/2025
ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant [...]
Alethio Therapeutics Launches with New CEO and Chair to Advance Two Targeted Medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)
30/10/2025
Leveraging deep scientific and clinical expertise in MPNs to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells Advancing AT-01, a first-in-class ADC programme, with [...]

Pages